Cabergoline, a dopamine agonist, is not approved for use in acromegaly, but it is occasionally prescribed for patients with mildly elevated IGF-I levels after surgery or as an add-on therapy when biochemical control is not achieved with the maximum doses of SRLs or PEG [21]. This evidence concerns the gene IGF1 and acromegaly.